Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

TAK-881

Other · developed by TAKEDA PHARMACEUTICAL CO

Phase 2/3 Most advanced trial (none active)

TAK Developer

1 Registered trials

What is TAK-881?

TAK-881 is an investigational drug studied in Primary Immunodeficiency Diseases (PID).

At a glance

Drug type: Other
Therapy area: Immunology
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05755035	Phase 2/3	Primary Immunodeficiency Diseases (PID)	Completed	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Immunodeficiency Diseases (PID)

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2

Sources

ClinicalTrials.gov NCT05755035

Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind TAK-881

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z